THE DEAL, AT A GLANCE
From the announcementArthrosi
01What it doesArthrosi is a Digital Health company focused on advance its phase 3 gout clinical trial, aiming for data release in 2026.From the announcement
Summarized from the deal record's source announcement; not yet independently reviewed.
Read the announcement ↗02What happenedArthrosi raised $153M Series E, announced 2025-10-08From the announcement
Summarized from the deal record's source announcement; not yet independently reviewed.
Read the announcement ↗03Why it mattersArthrosi's $153M Series E financing is a clinical-milestone financing tied to advancing its phase 3 gout clinical trial toward a 2026 data release.From the announcement
Summarized from the deal record's source announcement; not yet independently reviewed.
Read the announcement ↗Click a part to explore its evidence. Unsupported imagery is withheld rather than guessed.Original record source ↗
Arthrosi · Financing Record
Explore source-linked visual explanations for Arthrosi. Unsupported claims are withheld while source review continues.
Record 3453 · Recorded date: 2025-10-08
Explore company records →